相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment
Ester Pagano et al.
GUT (2022)
Self-made allostery: endogenous COMP antagonizes pathologic AT1AR signaling
Ama Dedo Okyere et al.
CELL RESEARCH (2021)
Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands
Hassan Nassour et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
A membrane-tethering pepducin derived from formyl peptide receptor 3 shows strong therapeutic effects against sepsis
Ha Young Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain
Rebecca L. Brouillette et al.
PHARMACOLOGICAL RESEARCH (2020)
PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization A Randomized, Placebo-Controlled, Phase 2 Study
Athan Kuliopulos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Dynamics of Cardiac Neutrophil Diversity in Murine Myocardial Infarction
Ehsan Vafadarnejad et al.
CIRCULATION RESEARCH (2020)
Targeting of G-protein coupled receptors in sepsis
Abdul Rehman et al.
PHARMACOLOGY & THERAPEUTICS (2020)
C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function
Yong Wang et al.
CIRCULATION (2019)
PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models
Travis P. Barr et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Biased Receptor Signaling in Drug Discovery
Terry Kenakin
PHARMACOLOGICAL REVIEWS (2019)
Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor
Mathilde Poujol de Molliens et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2019)
GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump
Georg Schneditz et al.
SCIENCE SIGNALING (2019)
Prior beta blocker treatment decreases leukocyte responsiveness to injury
Laurel A. Grisanti et al.
JCI INSIGHT (2019)
CB1 cannabinoid receptor-phosphorylated fourth intracellular loop structure-function relationships
Khalil Eldeeb et al.
PEPTIDE SCIENCE (2019)
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis
Rajashree Rana et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Krishna Sriram et al.
MOLECULAR PHARMACOLOGY (2018)
Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling
Laurel A. Grisanti et al.
THERANOSTICS (2018)
Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors
Verena Wieser et al.
GUT (2017)
G Protein-Coupled Receptor Kinase 3 and Protein Kinase C Phosphorylate the Distal C-Terminal Tail of the Chemokine Receptor CXCR4 and Mediate Recruitment of β-Arrestin
Jiansong Luo et al.
MOLECULAR PHARMACOLOGY (2017)
Trends in GPCR drug discovery: new agents, targets and indications
Alexander S. Hauser et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Formyl peptide derived lipopeptides disclose differences between the receptors in mouse and men and call the pepducin concept in question
Malene Winther et al.
PLOS ONE (2017)
Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling
Jialu Wang et al.
NATURE COMMUNICATIONS (2017)
FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils
Michael Gabl et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy
David M. Ryba et al.
CIRCULATION (2017)
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease
Paul A. Gurbel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
From biased signalling to polypharmacology: unlocking unique intracellular signalling using pepducins
Richard Carr et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
A pepducin designed to modulate P2Y2R function interacts with FPR2 in human neutrophils and transfers ATP to an NADPH-oxidase-activating ligand through a receptor cross-talk mechanism
Michael Gabl et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Leukocyte-Expressed β2-Adrenergic Receptors Are Essential for Survival After Acute Myocardial Injury
Laurel A. Grisanti et al.
CIRCULATION (2016)
Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin
Andrew M. Shearer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
β2-Adrenergic receptor-dependent chemokine receptor 2 expression regulates leukocyte recruitment to the heart following acute injury
Laurel A. Grisanti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
β-arrestin–biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction
Richard Carr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Interdicting Gq Activation in Airway Disease by Receptor-Dependent and Receptor-Independent Mechanisms
Richard Carr et al.
MOLECULAR PHARMACOLOGY (2016)
Data on human neutrophil activation induced by pepducins with amino acid sequences derived from β2AR and CXCR4
Andre Holdfeldt et al.
DATA IN BRIEF (2016)
A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead
Malene Winther et al.
FEBS LETTERS (2015)
Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics
Ping Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Mechanisms Underlying the Scratching Behavior Induced by the Activation of Proteinase-Activated Receptor-4 in Mice
Eliziane S. Patricio et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor
Jesus M. Planesas et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2015)
Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis
Cong Lin et al.
MOLECULAR MEDICINE (2015)
Endogenous Allosteric Modulators of G Protein-Coupled Receptors
Emma T. van der Westhuizen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Development and Characterization of Pepducins as Gs-biased Allosteric Agonists
Richard Carr et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
CXCR4 blockade induces atherosclerosis by affecting neutrophil function
Ilze Bot et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2014)
A Pepducin Derived from the Third Intracellular Loop of FPR2 Is a Partial Agonist for Direct Activation of This Receptor in Neutrophils But a Full Agonist for Cross-Talk Triggered Reactivation of FPR2
Michael Gabl et al.
PLOS ONE (2014)
Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis
Cong Lin et al.
THORAX (2014)
The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop
Huamei Forsman et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Identification of a pepducin acting as S1P3 receptor antagonist
Beatrice Severino et al.
JOURNAL OF PEPTIDE SCIENCE (2013)
FRET-based imaging of transbilayer movement of pepducin in living cells by novel intracellular bioreductively activatable fluorescent probes
Mieko Tsuji et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2013)
Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein
Julie Quoyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia
Katie O'Callaghan et al.
BLOOD (2012)
Suppression of Arterial Thrombosis Without Affecting Hemostatic Parameters With a Cell-Penetrating PAR1 Pepducin
Ping Zhang et al.
CIRCULATION (2012)
Proteinase-activated receptor 2 (PAR2) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level
Roland Kaufmann et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2012)
Turning Receptors On and Off with Intracellular Pepducins: New Insights into G-protein-coupled Receptor Drug Development
Katie O'Callaghan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
Thomas Jamieson et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Targeting Protease-Activated Receptor-1 with Cell-Penetrating Pepducins in Lung Cancer
Jaroslaw Cisowski et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Protease-Activated Receptor-2 Modulates Protease-Activated Receptor-1-Driven Neointimal Hyperplasia
Leila M. Sevigny et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
G Protein-Dependent and G Protein-Independent Signaling Pathways and Their Impact on Cardiac Function
Douglas G. Tilley
CIRCULATION RESEARCH (2011)
Direct Interaction between an Allosteric Agonist Pepducin and the Chemokine Receptor CXCR4
Jay M. Janz et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Double-Edged Role of the CXCL12/CXCR4 Axis in Experimental Myocardial Infarction
Elisa A. Liehn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Possible role of autoimmune reaction in Modic Type I changes
Xin-Long Ma et al.
MEDICAL HYPOTHESES (2011)
Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins
Leila M. Sevigny et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Activation of human monocytes by a formyl peptide receptor 2-derived pepducin
Ha Young Lee et al.
FEBS LETTERS (2010)
Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells
Boris Tchernychev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Blockade of PAR1 Signaling with Cell-Penetrating Pepducins Inhibits Akt Survival Pathways in Breast Cancer Cells and Suppresses Tumor Survival and Metastasis
Eric Yang et al.
CANCER RESEARCH (2009)
Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis
Alma Zernecke et al.
CIRCULATION RESEARCH (2008)
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer
Anika Agarwal et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation
Sjoukje H. Slofstra et al.
BLOOD (2007)
Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists
S. J. H. Wielders et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Protease-activated receptors in cardiovascular diseases
Andrew J. Leger et al.
CIRCULATION (2006)
Reversing systemic inflammatory response syndrome with chemokine receptor pepducins
NC Kaneider et al.
NATURE MEDICINE (2005)
Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis
A Kuliopulos et al.
LIFE SCIENCES (2003)
Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation
L Covic et al.
NATURE MEDICINE (2002)
Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides
L Covic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
